US equities |
MU $953.19 ▲+0.00% SNDK $1,482.33 ▲+0.00% ASML $1,717.76 ▲+0.00% NVDA $228.52 ▲+0.00% SPCX $156.54 ▲+0.00% SKHY $157.06 ▲+0.00% AMD $605.53 ▲+0.00% INTC $102.81 ▲+0.00%
FinancialContent

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

14.92 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE
From Robbins LLP
Via GlobeNewswire
News headline image
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE
From Pomerantz LLP
Via GlobeNewswire
Ultragenyx Pharmaceutical (NASDAQ:RARE) Posts Q4 Revenue Beat, Wider Loss, and Announces Restructuring ↗
Via Chartmill
News headline image
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges RARE Investors With Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges RARE Investors With Losses to Contact the Firm
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RARE Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
RARE Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty ↗
Ultragenyx said on Thursday that the FDA has again refused approval for UX111 in the treatment of Sanfilippo syndrome type A. 
Via Stocktwits
News headline image
Class Action Announcement RARE: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Announcement RARE: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Did you buy RARE common stock between August 3, 2023, and December 26, 2025? 
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript ↗
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline in Securities Fraud Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action
From Robbins LLP
Via GlobeNewswire
News headline image
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE
From DJS Law Group
Via Business Wire
News headline image
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >